Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis

NCT01785186 is registered in ClinicalTrials.gov with Michael Hoelscher as lead sponsor.

NCT NCT01785186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01785186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis
Lead sponsor
Michael Hoelscher
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2013
Completion date
March 31, 2015
Enrollment
365 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis, pulmonary